...
首页> 外文期刊>Infection and immunity >LcrV Delivered via Type III Secretion System of Live Attenuated Yersinia pseudotuberculosis Enhances Immunogenicity against Pneumonic Plague
【24h】

LcrV Delivered via Type III Secretion System of Live Attenuated Yersinia pseudotuberculosis Enhances Immunogenicity against Pneumonic Plague

机译:通过活的减毒耶尔森氏菌假结核耶尔森氏菌III型分泌系统递送的LcrV增强了抵抗肺炎鼠疫的免疫原性。

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Here, we constructed a Yersinia pseudotuberculosis mutant strain with arabinose-dependent regulated and delayed shutoff of crp expression (araC PBAD crp) and replacement of the msbB gene with the Escherichia coli msbB gene to attenuate it. Then, we inserted the asd mutation into this construction to form χ10057 [Δasd-206 ΔmsbB868::PmsbB msbB(EC) ΔPcrp21::TT araC PBAD crp] for use with a balanced-lethal Asd-positive (Asd+) plasmid to facilitate antigen synthesis. A hybrid protein composed of YopE (amino acids [aa]1 to 138) fused with full-length LcrV (YopENt138-LcrV) was synthesized in χ10057 harboring an Asd+ plasmid (pYA5199, yopENt138-lcrV) and could be secreted through a type III secretion system (T3SS) in vitro and in vivo. Animal studies indicated that mice orally immunized with χ10057(pYA5199) developed titers of IgG response to whole-cell lysates of Y. pestis (YpL) and subunit LcrV similar to those seen with χ10057(pYA3332) (χ10057 plus an empty plasmid). However, only immunization of mice with χ10057(pYA5199) resulted in a significant secretory IgA response to LcrV. χ10057(pYA5199) induced a higher level of protection (80% survival) against intranasal (i.n.) challenge with ~240 median lethal doses (LD50) (2.4 × 104 CFU) of Y. pestis KIM6+(pCD1Ap) than χ10057(pYA3332) (40% survival). Splenocytes from mice vaccinated with χ10057(pYA5199) produced significant levels of gamma interferon (IFN-γ), tumor necrosis factor alpha (TNF-α), and interleukin-17 (IL-17) after restimulation with LcrV and YpL antigens. Our results suggest that it is possible to use an attenuated Y. pseudotuberculosis strain delivering the LcrV antigen via the T3SS as a potential vaccine candidate against pneumonic plague.
机译:在这里,我们构建了一种由阿拉伯糖依赖性调节和延迟关闭 crp 表达( araC P BAD crp < / em>),并用大肠杆菌 msbB 基因替换 msbB 基因以使其减弱。然后,我们将 asd 突变插入此结构中,形成χ10057[Δ asd-206 Δ msbB868 :: P msbB msbB (EC)ΔP crp21 :: TT araC P BAD < em> crp ]用于平衡致死性Asd阳性(Asd + )质粒以促进抗原合成。在带有Asd + 的χ10057中合成了由YopE(氨基酸[aa] 1至138)与全长LcrV(YopE -LcrV)融合的杂合蛋白。质粒(pYA5199, yopE Nt138 -lcrV ),可通过III型分泌系统(T3SS)在体外 分泌体内。动物研究表明,经χ10057(pYA5199)口服免疫的小鼠产生了对鼠疫耶尔森氏菌(YpL)和LcrV亚基全细胞裂解液的IgG效价,与χ10057(pYA3332)(χ10057加空质粒)相似。然而,仅用χ10057(pYA5199)免疫小鼠会导致对LcrV的显着分泌性IgA反应。 χ10057(pYA5199)在约240致死剂量(LD 50 )(2.4×10 4 )中对鼻内攻击具有更高的保护水平(80%存活)鼠疫耶尔森氏菌KIM6 +(pCD1Ap)比χ10057(pYA3332)的CFU)(存活率40%)。在用LcrV和YpL抗原重新刺激后,接种χ10057(pYA5199)的小鼠的脾细胞产生了显着水平的γ干扰素(IFN-γ),肿瘤坏死因子α(TNF-α)和白介素17(IL-17)。我们的结果表明,有可能使用通过T3SS递送LcrV抗原的减毒假结核耶尔森氏菌菌株作为抗肺炎鼠疫的潜在候选疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号